



JOINT TRIAL EXHIBIT LIST

____ Government ____ Plaintiff ____ Defendant ____ Joint ____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-576						Gupta, S et al. Weight decline in patients switching from olanzapine to quetiapine. <i>Schizophrenia Research</i> . 2004; 70: 57-62.
D-577						Harvey, P et al. Improvement in Social Competence with Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison Quetiapine Versus Risperidone for Social Cognition, and Neuropsychological Functioning. <i>American Journal of Psychiatry</i> . 2006; 163: 1918-1925.
D-578						Hellewell J et al. Patient Satisfaction and Acceptability of Long-Term Treatment with Quetiapine. <i>International Journal of Psychiatry in Clinical Practice</i> . 1999; 3: 105-113.
D-579						Henderson, D et al. Glucose Metabolism in Patients With Schizophrenia Treated With Olanzapine or Quetiapine: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis. <i>Journal of Clinical Psychiatry</i> . 2006; 67: 789-797.
D-580	Harnill 45					Hirschfeld, R et al. Validity of the Mood Disorder Questionnaire: A General Population Study. <i>American Journal of Psychiatry</i> . 2003; 160: 178-180.
D-581						Hirschfeld, R et al. Quetiapine in the Treatment of Anxiety in Patients With Bipolar I or II Depression: A Secondary Analysis From a Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of Clinical Psychiatry</i> . 2006; 67: 355-362.
D-582						Jamison, R. Suicide and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> . 2000; 61(9): 47-51.
D-583						Johnson, D et al. Diabetic Ketoacidosis in a Community-Based Population. <i>Mayo Clinic Proceedings</i> . 1980; 55: 83-88.
D-584						Joyce, M. Efficacy and Safety of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Generalized Anxiety Disorder (GAD). 2008. Abstract Poster
D-585						Juncos, J et al. Quetiapine Improves Psychotic Symptoms and Cognition in Parkinson's Disease. <i>Movement Disorders</i> . 2004; 19(1): 29-35.



JOINT TRIAL EXHIBIT LIST

____ Government ____ Plaintiff ____ Defendant ____ Joint ____ Court
 Case No. 6:06-cv-1769-ACC-DAB
Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-586						Kahn, A et al. Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in the Treatment of Patients with Generalized Anxiety Disorder (GAD). 2008. Abstract Poster.
D-587						Kahn, R et al. Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of Clinical Psychiatry</i> . 2007; 68: 832-842.
D-588						Kahn, R et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. <i>The Lancet</i> . 2008; 371: 1085-1097.
D-589						Kasper, S et al. Quetiapine: Efficacy and Tolerability in Schizophrenia. <i>European Neuropsychopharmacology</i> . 2001; 4: S405-S413.
D-590						Katzman, M et al. Extended Release Quetiapine Fumarate (quetiapine XR) Monotherapy in Maintenance Treatment of Generalized Anxiety Disorder (GAD): Efficacy and Tolerability Results from a Randomized, Placebo-Controlled Trial. 2008. Abstract Poster.
D-591						Keck, P. Treatment of Bipolar Disorder. Chapter 3 from <i>Textbook of Psychopharmacology</i> . Third Edition. 2004. American Psychiatric Publishing.
D-592						Keck, P. The Role of Second-Generation Anti-Psychotic Monotherapy in the Rapid Control of Acute Bipolar Mania. <i>Journal of Clinical Psychiatry</i> . 2005; 66(3): 5-11.
D-593						King, D et al. A Comparison of bid and tid Dose Regimens of Quetiapine (Seroquel) in the Treatment of Schizophrenia. <i>Psychopharmacology</i> . 1998; 137: 139-146.
D-594						Kinon, B et al. Long-Term Olanzapine Treatment: Weight Change and Weight-Related Health Factors in Schizophrenia. <i>Journal of Clinical Psychiatry</i> . 2001; 62: 92-100.



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-595						Knegtering, R et al. A Randomized Open-Label Study of the Impact of Quetiapine versus Risperidone on Sexual Functioning. <i>Journal of Clinical Psychopharmacology</i> . 2004; 24: 56-61.
D-596					Relevance; Prejudicial; Hearsay; Hearsay within hearsay	Koller, E et al. Olanzapine-Associated Diabetes Mellitus. <i>Pharmacotherapy</i> . 2002; 22(7): 841-852
D-597						Koller, E et al. Risperidone-Associated Diabetes Mellitus: A Pharmacovigilance Study. <i>Pharmacotherapy</i> . 2003; 23(6): 735-744
D-598						Kopala, L et al. Treatment of a First Episode of Psychotic Illness with Quetiapine: An Analysis of 2 year Outcomes. <i>Schizophrenia Research</i> . 2005; published online: 1-11.
D-599	Fors 17, Limp 38, Limp 40, Limp 42, Limp 48, Warner 21, Hirschfield 16, Reinstein 42				Relevance; Prejudicial; Hearsay; Hearsay within hearsay	Scrip, "Seroquel Dear Doctor Letter in Japan," Nov. 8, 2002. (AZSER 10095980-AZSER 10095981)
D-600						Kowatch, R et al. Treatment Guidelines for Children and Adolescents with Bipolar Disorder. <i>Journal of American Children Adolescent Psychiatry</i> . 2005; 44(4): 213-235.
D-601						Kwon, J et al. Weight Management Program for Treatment-Emergent Weight Gain in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder: A 12-Week Randomized Controlled Clinical Trial. <i>Journal Clinical of Psychiatry</i> . 2006; 67: 547-553.
D-602						Lambert, B et al. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. <i>Pharmacoepidemiology and Drug Safety</i> . 2005; 14(6): 417-425. (J-15)



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-603						Lambert, M et al. New-onset type-2 diabetes associated with atypical antipsychotic medications. <i>Progress in Neuro-Psychopharmacology & Biological Psychiatry</i> . 2006; 30: 919-923.
D-604						Lamberti, J et al. Prevalence of Diabetes Mellitus Among Outpatients With Severe Mental Disorders Receiving Atypical Antipsychotic Drugs. <i>Journal of Clinical Psychiatry</i> . 2004; 65: 702-706.
D-605						Laughren, T.P. The Scientific and Ethical Basis for Placebo Controlled Trials in Depression and Schizophrenia: An FDA Perspective. <i>European Psychiatry</i> . 2001; 16: 418-23.
D-606						Lebovitz, H. Insulin Secreagogues: Old and New. <i>Diabetes Reviews</i> . 1999; 7(3): 139-153.
D-607						Lee, P et al. Long-Term, Naturalistic Treatment with Olanzapine, Risperidone, Quetiapine, or Haloperidol Monotherapy: 24-Month Results from the Intercontinental Schizophrenia Outpatient Outcomes (IC-SOHO) Study. <i>International Journal of Psychiatry in Clinical Practice</i> . 2008; 12(3): 215-227.
D-608						Lehman, A et al. The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003. <i>Schizophrenia Bulletin</i> . 2004; 30 (2): 193-217.
D-609						Leslie, D et al. Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications. <i>American Journal of Psychiatry</i> . 2004; 161: 1709-1711. (1-16)
D-610						Letter to the Editor from Deanna Kelly. Six Month Review of Weight and Metabolic Parameters in Patients Receiving Clozapine, Risperidone, Olanzapine, or Quetiapine. <i>Journal of Clinical Psychiatry</i> . 2003; 64(9): 1130-1134.
D-611						Lieberman, J et al. Drugs of Psychopharmacological Revolution in Clinical Psychiatry. <i>Psychiatric Services</i> . 2000; 51(10): 1254-1258.



JOINT TRIAL EXHIBIT LIST

____ Government ____ Plaintiff ____ Defendant X Joint ____ Court
 Case No. 6:06-cv-1769-ACC-DAB
Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-612						Lieberman, J et al. Comparison of Atypicals in First-Episode Psychosis: A Randomized, 52 Week Comparison of Olanzapine, Quetiapine, and Risperidone. 2005; S526.
D-613	Birkett 52					Lieberman, J et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. <i>NEJM</i> . 2005; 353 (12): 1209-23.
D-614						Liliker, S. Prevalence of Diabetes in a Manic-Depressive Population. <i>Comprehensive Psychiatry</i> . 1980; 21(4): 270-275.
D-615						Lindemayer, J.P. et al. Changes in Glucose and Cholesterol Levels in Patients with Schizophrenia Treated with Typical or Atypical Antipsychotics. <i>American Journal of Psychiatry</i> . 2003; 160: 290-296.
D-616						Lorenz, W.F. Sugar Tolerance in Dementia Praecox and Other Mental Disorders. <i>Archives of Neurology and Psychiatry</i> . 1921. 184-196.
D-617						Marchand, W et al. Quetiapine Adjunctive and Monotherapy for Pediatric Bipolar Disorder: A Retrospective Chart Review. <i>Journal of Child and Adolescent Psychopharmacology</i> . 2004; 14(3): 405-411.
D-618						Martin, B et al. Role of Glucose and Insulin Resistance in Development of Type 2 Diabetes Mellitus: Results of a 25-Year Follow-Up Study. <i>The Lancet</i> . 1992; 340: 925-29.
D-619						MeEvoy, J et al. Expert Consensus Guideline Series Treatment of Schizophrenia 1999. <i>Journal of Clinical Psychiatry</i> . 1999; 60 (11): 1-83.
D-620						MeEvoy, J et al. Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> . 2006; 163: 600-610. (J-17)
D-621						MeEvoy, J et al. Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52 Week Comparison. <i>American Journal of Psychiatry</i> . 2007; 164: 1050-1060. (J-18)



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-622						Melnyre, R. Quetiapine or Haloperidol as Monotherapy for Bipolar Mania -- a 12 Week, Double Blind, Randomised, Parallel-Group, Placebo-Controlled Trial. <i>European Neuropsychopharmacology</i> . 2005; 15: 573-585.
D-623						McManus, D et al. Quetiapine, A Novel Antipsychotic: Experience in Elderly Patients with Psychotic Disorders. <i>Journal of Clinical Psychiatry</i> . 1999; 60(5): 292-298.
D-624						Meats, P. Quetiapine (Seroquel): An Effective and Well-Tolerated Atypical Antipsychotic. <i>International Journal of Psychiatry in Clinical Practice</i> . 1997; 1: 231-239.
D-625						Meyer JM, et al. Change in Metabolic Syndrome Parameters with Antipsychotic Treatment in the CATIE Schizophrenia Trial: Prospective Data from Phase I." <i>Schizophrenia Research</i> 2008, in press.
D-626						Miller, A et al. The Texas Medication Algorithm Project (TMAP) Schizophrenia Algorithms. <i>Journal of Clinical Psychiatry</i> . 1999; 60(10): 649-657.
D-627						Miller, A et al. The Texas Medication Algorithm for Schizophrenia: 2003 Update. <i>Journal of Clinical Psychiatry</i> . 2004; 65: 500-508.
D-628						Miller, E et al. Incidence of New-Onset Diabetes Mellitus Among Patients Receiving Atypical Neuroleptics in the Treatment of Mental Illness. <i>Journal of Nervous and Mental Disease</i> . 2005; 193: 387-395.
D-629						Mishra, G et al. Short-Term Weight Change and the Incidence of Diabetes in Midlife. <i>Diabetes Care</i> . 2007; 30: 1418-1424.
D-630						Moneva, M.H. et al. Multiple Drug Targets in the Management of Type 2 Diabetes. <i>Current Drug Targets</i> . 2002; 3: 203-221.
D-631						Moore, T et al. The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update. <i>Journal of Clinical Psychiatry</i> . 2007; 68 (11): 1751-1762.



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-632						Mukaddes, N et al. Quetiapine Treatment of Children and Adolescents with Tourette's Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> . 2003; 13(3): 295-299.
D-633						Mukherjee, S et al. Diabetes Mellitus in Schizophrenic Patients. <i>Comprehensive Psychiatry</i> . 1996; 37(1): 68-73.
D-634						Mullen, J et al. A Comparison of the Relative Safety, Efficacy, and Tolerability of Quetiapine and Risperidone in Outpatients with Schizophrenia and Other Psychotic Disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) Study. <i>Clinical Therapeutics</i> . 2001; 23(11): 1839-1854.
D-635						Murasaki, M. Efficacy and Tolerability of Quetiapine Compared with Haloperidol in Patients with Schizophrenia.
D-636						Narayan, KMV, et al. Effect of Body Mass Index On Lifetime Risk For Diabetes Mellitus In The United States. <i>Diabetes Care</i> . 2007; 30(6): 1562-1566
D-637	Nasrallah 19					Nasrallah, H. Efficacy, Safety, and Tolerability of Quetiapine in Patients with Schizophrenia. <i>Journal of Clinical Psychiatry</i> . 2002; 63(suppl.13): 12-20.
D-638	Nasrallah 18					Nasrallah, H. A Review of the Effect of Atypical Antipsychotics on Weight. <i>Psychoneuroendocrinology</i> . 2003; 28: 83-96.
D-639						Nasrallah, H. Metabolic Findings From the CATIE Trial and Their Relation to Tolerability. <i>CNS Spectator</i> . 2006; 11(Suppl. 7): 32-39.
D-640						National Diabetes Data Group. Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance. <i>Diabetes</i> . 1979; 28: 1038-1057.
D-641						National Diabetes Fact Sheet. 2007. Published Online: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf
D-642						Newcomer, J. Second Generation (Atypical) Antipsychotics and Metabolic Effects. <i>CNS Drugs</i> . 2005; 19(1): 1-93.
D-643						Norton, B et al. Mortality of a Lithium-Treated Population. <i>British Journal of Psychiatry</i> . 1984; 145: 277-282.



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-644						Ollendorf, D et al. Rate of New-Onset Diabetes Among Patients Treated With Atypical or Conventional Antipsychotic Medications for Schizophrenia. <i>Medical Science General Medicine</i> . 2004; 6(1): 1-12.
D-645						Ollerton, R et al. Day-to-Day Variability of Fasting Plasma Glucose in Newly Diagnosed Type 2 Diabetic Subjects. <i>Diabetes Care</i> . 1999; 22: 394-398.
D-646						Osbye, T et al. Atypical Antipsychotic Drugs and Diabetes Mellitus in a Large Outpatient Population: A Retrospective Cohort Study. <i>Pharmacoepidemiology and Drug Safety</i> . 2005; 14(6): 407-415.
D-647						Patel, N et al. A Retrospective Analysis of the Short-Term Effects of Olanzapine and Quetiapine on Weight and Body Mass <i>Index in Children and Adolescents. Pharmacotherapy</i> . 2004; 24(7): 824-830.
D-648						Peuskens, J. A Comparison of Quetiapine and Chlorpromazine in the Treatment of Schizophrenia. <i>Acta Psychiatrica Scandinavica</i> . 1997; 96: 265-272.
D-649						Peuskens, J et al. Prevention of Schizophrenia Relapse with Extended Release Quetiapine Fumarate Dosed Once Daily: A Randomized, Placebo-Controlled Trial in Clinically Stable Patients. <i>Psychiatry (MMC)</i> . 2007; published online: 1-17.
D-650						Peuskens, J et al. Long-term Symptomatic Remission of Schizophrenia with Once-Daily Extended Release Quetiapine Fumarate. <i>Schizophrenia Research</i> . 2008; 98: 14-15.
D-651						Pink Sheet. (AZSER 10096462-AZSER 10096464)
D-652						Planansky, K. Changes in Weight in Patients Receiving a Tranquilizing Drug. <i>Psychiatry Quarterly</i> . 1958; 32: 289-303.
D-653						Practice Guidelines for the Treatment of Patients with Schizophrenia. American Psychiatric Association Practice Guidelines. <i>American Journal of Psychiatry</i> . 1997; 154(4): 1-63.



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Supulated Admissions	Description of Exhibit
D-654						Ratner, R et al. Differential Effects of Quetiapine, Olanzapine and Risperidone on Glucose Metabolism in Patients with Schizophrenia: Results from a 24-Week Randomized Study (Abstract 124). <i>ACNP 2006 Annual Meeting</i>
D-655						Regenold, W et al. Increased Prevalence of Type II Diabetes Mellitus Among Psychiatric Inpatients with Bipolar I Affective and Schizoaffective Disorders Independent Psychotropic Drug Use. <i>Journal of Affective Disorders</i> . 2002; 70: 19-26.
D-656	Gaskill 49, Hamill 19, Reinstein 5					Reinstein, M et al. Effect of Clozapine-Quetiapine Combination Therapy on Weight and Glycaemic Control. Preliminary Findings. <i>Clinical Drug Investigation</i> . 1999; 18(2): 99-104.
D-657						Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. <i>Diabetes Care</i> . 2003; 26 (suppl. 1): s5-s20.
D-658						Resnick, H et al. Relation of Weight Gain and Weight Loss on Subsequent Diabetes Risk in Overweight Adults. <i>Journal of Epidemiology and Community Health</i> . 2000; 54: 596-602.
D-659						Riedel, M et al. Quetiapine Has Equivalent Efficacy and Superior Tolerability to Risperidone in the Treatment of Schizophrenia with Predominantly Negative Symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> 2008; published online: 1-6.
D-660						Rosenheck, R et al. Does Switching to a New Anti-Psychotic Improve Outcomes? <i>Schizophrenia Research</i> . 2008; published online: 1-8.
D-661						Ryan, M et al. Impaired Fasting Glucose Tolerance in First-Episode Drug-Naïve Patients with Schizophrenia. <i>American Journal of Psychiatry</i> . 2003; 160: 284-289.
D-662						Ryan, M et al. Physical Consequences of Schizophrenia and its Treatment: The Metabolic Syndrome. <i>Life Sciences</i> . 2002; 71:239-257.
D-663						Sachs, G et al. Quetiapine with Lithium or Divalproex for the Treatment of Bipolar Mania: A Randomized, Double Blind, Placebo Controlled Study. <i>Bipolar Disorders</i> . 2004; 6: 213-223.



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff X Defendant _____ Joint _____ Court _____
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-664						Schatzberg, A. <i>Textbook of Psychopharmacology</i> . The American Psychiatric Publishing Company, 2004, Third edition.
D-665						Schneider, L. Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. <i>NEJM</i> . 2006; 355(15): 1525-38.
D-666						Schulz, C et al. The Efficacy of Quetiapine vs. Haloperidol and Placebo: a Meta-Analytic Study of Efficacy. <i>Schizophrenia Research</i> 2003; 62: 1-12.
D-667						Sernyak, M. Letter to the Editor. Diabetes and Atypical Neuroleptics. <i>American Journal of Psychiatry</i> . 2003; 160(2): 388.
D-668						Sernyak, M. Undiagnosed Hyperglycemia in Patients Treated with Atypical Antipsychotics. <i>Journal of Clinical Psychiatry</i> . 2005; 66: 1463-1467. (J-19)
D-669						Sirota, P et al. Quetiapine versus Olanzapine for the Treatment of Negative Symptoms in Patients with Schizophrenia. <i>Human Psychopharmacology: Clinical and Experimental</i> . 2006; 21: 227-234.
D-670						Small, J et al. Quetiapine in Patients with Schizophrenia. <i>Archives of General Psychiatry</i> . 1997; 54: 549-557.
D-671						Sowell, M et al. Hyperglycemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo. <i>Journal of Clinical Endocrinology and Metabolism</i> . 2002; 87: 2918-2923.
D-672						Sowell, M et al. Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo: A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp. <i>Journal of Clinical Endocrinology and Metabolism</i> 2003; 88: 5875-5880.
D-673						Spelman, L.M. et al. Impaired Glucose Tolerance in First-Episode Drug-Native Patients with Schizophrenia. <i>Diabetic Medicine</i> . 2007; 24: 481-485.



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-674						Strom, B. Study Designs Available for Pharmacoepidemiology Studies. <i>Pharmacoepidemiology</i> . Philadelphia: John Wiley & Sons, 2005. 17-28.
D-675						Stroup, T et al. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> . 2006; 163: 611-622. (J-20)
D-676						Stroup, T et al. Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study. <i>American Journal of Psychiatry</i> . 2007; 164: 415-427. (J-21)
D-677						Sussman, N. Review of Atypical Antipsychotics and Weight Gain. <i>Journal of Clinical Psychiatry</i> . 2001; 62(23): 5-12.
D-678						Taubes, G et al. Epidemiology Faces Its Limits. <i>Science</i> . 2000; 269: 164-169.
D-679						Taylor, E et al. Antihypertensive Medications and the Risk of Incident Type 2 Diabetes. <i>Diabetes Care</i> . 2006; 29:1065-1070.
D-680						Thakore, J.H. et al. Increased Visceral Fat Distribution in Drug-Naïve and Drug-Free Patients with Schizophrenia. <i>International Journal of Obesity</i> . 2002; 26:137-141.
D-681						Thase, M et al. Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression: A Double-blind, Placebo-controlled Study (The BOLDER II Study). <i>Journal of Clinical Psychopharmacology</i> . 2006; 26: 600-609.
D-682						Troisi RJ, et al. Diurnal Variation in Fasting Plasma Glucose: Implications for Diagnosis of Diabetes in Patients Examined in the Afternoon. <i>JAMA</i> . 2000; 284(24): 3157-3159.
D-683						Umbricht, D et al. Clozapine and Weight Gain. <i>Journal of Clinical Psychiatry</i> . 1994; 55(suppl B): 157-160.
D-684						US Department of Health and Human Services "Quick Information for Your Health on Diabetes."



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-685						US Department of Health and Human Services. <i>Mental Health: A Report of the Surgeon General</i> . Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, NIH, National Institute of Mental Health, 1999.
D-686						van Nimwegen, L et al. Hepatic Insulin Resistance in Antipsychotic Naïve Schizophrenic Patients: Stable Isotope Studies of Glucose Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> . 2008; 93:572-577.
D-687						Velligan, D et al. Does Cognitive Function Improve with Quetiapine in Comparison with Haloperidol? <i>Schizophrenia Research</i> . 2002; 53: 239-248.
D-688						Vieta, E et al. Efficacy and Safety of Quetiapine in Combination with Lithium or Divalproex for Maintenance of Patients with Bipolar I Disorder (International Trial 126). <i>Journal of Affective Disorders</i> . 2008; 109: 251-263.
D-689						Waitzkin, I, et al. A Survey for Unknown Diabetes in a Mental Hospital. <i>Diabetes</i> . 1966; 15: 97-104.
D-690						Wannamethee SG, et al. Weight Change and Duration of Overweight and Obesity in the Incidence of Type II Diabetes. <i>Diabetes Care</i> . 1999; 28(8): 1266-1272.
D-691						Weisler, R et al. Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy for Major Depressive Disorder (MDD): A Double Blind, Placebo Controlled Study. 2008. Abstract Poster.
D-692						Westheide, J et al. Prolactin, Subjective Well-Being and Sexual Dysfunction: An Open Label Observational Study Comparing Quetiapine with Risperidone. <i>Journal of Sex Medicine</i> ; published online: 1-8.
D-693						Wetterling, T et al. Weight Gain: Side Effect of Atypical Neuroleptics. <i>Journal of Clinical Psychopharmacology</i> . 1999; 19(4): 316-321.



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-694						Willi, C et al. Active Smoking and the Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>JAMA</i> . 2007; 298(22): 2654-2664.
D-695						Woo, V. Canadian Diabetes Association Position Paper: Antipsychotic Medications and Associated Risks of Weight Gain and Diabetes. <i>Canadian Journal of Diabetes</i> . 2005; 29(2): 111-112.
D-696						Wu, RR et al. Lifestyle Intervention and Metformin for Treatment of Antipsychotic-induced Weight Gain: A Randomized Controlled Trial. <i>JAMA</i> 2008; 299: 185-93.
D-697						Yatham, L et al. Quetiapine Versus Placebo in Combination With Lithium or Divalproex for the Treatment of Bipolar Mania. <i>Journal of Clinical Psychopharmacology</i> . 2004; 24(6): 599-606.
D-698						Zhong, K et al. Comparison of Quetiapine and Risperidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Flexible-Dose, 8-Week Study. <i>Journal of Clinical Psychiatry</i> . 2006; 67: 1093-1103.
D-699					Hearsay	4/7/09. Newcomer J et al., A 24-Week, Multicenter, Open-Label Randomized Study To Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone. <i>J Clin Psychiatry</i> April 7, 2009; e1-e13 (pii: ej008m04132)
D-700						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-701						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-702						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-703						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-704						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-705						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-706						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-707						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-708						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-709						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-710						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-711						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-712						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-713						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-714						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-715						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-716						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-717						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-718						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-719						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-720						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-721						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-722						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-723						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-724						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-725						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-726						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-727						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-728						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-729						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-730						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-731						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-732						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-733						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-734						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-735						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-736						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-737						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-738						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-739						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-740						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-741						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-742						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-743						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-744						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-745						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-746						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-747						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-748						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-749						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-750						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-751						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-752						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-753						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-754						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-755						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-756						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-757						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-758						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-759						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-760						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-761						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-762						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-763						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-764						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-765						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-766						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-767						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-768						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-769						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-770						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-771						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-772						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-773						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant X Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-774						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-775						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-776						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-777						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-778						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-779						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-780						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-781						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-782						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-783						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-784						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-785						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-786						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-787						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-788						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-789						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-790						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-791						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-792						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-793						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-794						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-795						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-796						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-797						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-798						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-799						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-800						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-801						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-802						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-803						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-804						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-805						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-806						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-807						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-808						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-809						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-810						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-811						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-812						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-813						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-814						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-815						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-816						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-817						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-818						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-819						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-820						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-821						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-822						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-823						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-824						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-825						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-826						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-827						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-828						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-829						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-830						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-831						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-832						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-833						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-834						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-835						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-836						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-837						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-838						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-839						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-840						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-841						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-842						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-843						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-844						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-845						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-846						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-847						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-848						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-849						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-850						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-851						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-852						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-853						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-854						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-855						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-856						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-857						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-858						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-859						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-860						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-861						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-862						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-863						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-864						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-865						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-866						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-867						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-868						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-869						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-870						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-871						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-872						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-873						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-874						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-875						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-876						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-877						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-878						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-879						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-880						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-881						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-882						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-883						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-884						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-885						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-886						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-887						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-888						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-889						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-890						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-891						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-892						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-893						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-894						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-895						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-896						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-897						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-898						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-899						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-900						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-901						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-902						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-903						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-904						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-905						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-906						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-907						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-908						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-909						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-910						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-911						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-912						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-913						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-914						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-915						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-916						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-917						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-918						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-919						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-920						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-921						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-922						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-923						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-924						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-925						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-926						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-927						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-928						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-929						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-930						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-931						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-932						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-933						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-934						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-935						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-936						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-937						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-938						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-939						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-940						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-941						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-942						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-943						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-944						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-945						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-946						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-947						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-948						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-949						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-950						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-951						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-952						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-953						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-954						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-955						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-956						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-957						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-958						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-959						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-960						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-961						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-962						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-963						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-964						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-965						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-966						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-967						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-968						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-969						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-970						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-971						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-972						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-973						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-974						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-975						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-976						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-977						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-978						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-979						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-980						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-981						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-982						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-983						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-984						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-985						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-986						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-987						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-988						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-989						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-990						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-991						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-992						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-993						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-994						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-995						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-996						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-997						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-998						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-999						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1000						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1001						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1002						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1003						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1004						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1005						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1006						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1007						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1008						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1009						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1010						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1011						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1012						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1013						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1014						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1015						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1016						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1017						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1018						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1019						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1020						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1021						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1022						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1023						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1024						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1025						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1026						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1027						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1028						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1029						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1030						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1031						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1032						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1033						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1034						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1035						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1036						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1037						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1038						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1039						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1040						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1041						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1042						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1043						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1044						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1045						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1046						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1047						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1048						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1049						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1050						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1051						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1052						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1053						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1054						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1055						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1056						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1057						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1058						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1059						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1060						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1061						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1062						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1063						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1064						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1065						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1066						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1067						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1068						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1069						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1070						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1071						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1072						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1073						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1074						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1075						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1076						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1077						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1078						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1079						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1080						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1081						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1082						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1083						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1084						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1085						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1086						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1087						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1088						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1089						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1090						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1091						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1092						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1093						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1094						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1095						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1096						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1097						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1098						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1099						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1100						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1101						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1102						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1103						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1104						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1105						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1106						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1107						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1108						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1109						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1110						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1111						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1112						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1113						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1114						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1115						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1116						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1117						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1118						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1119						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1120						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1121						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1122						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1123						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1124						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1125						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1126						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1127						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1128						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1129						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1130						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1131						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1132						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1133						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1134						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1135						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1136						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1137						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1138						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1139						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1140						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1141						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1142						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1143						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1144						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1145						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1146						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1147						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1148						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1149						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1150						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1151						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1152						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1153						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1154						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1155						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1156						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1157						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION


No.	Trial Exhibit	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1158							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1159							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1160							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1161							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1162							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1163							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1164							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1165							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1166							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1167							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1168							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1169							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1170							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1171							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1172							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1173							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1174							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1175							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1176							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1177							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1178							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1179							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1180							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1181							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1182							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1183							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1184							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1185							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1186							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1187							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1188							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1189							RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1190						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1191						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1192						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1193						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1194						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1195						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1196						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1197						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1198						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1199						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1200						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1201						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1202						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1203						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1204						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1205						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1206						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1207						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1208						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1209						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1210						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1211						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1212						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1213						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1214						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1215						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1216						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1217						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1218						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1219						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1220						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1221						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1222						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1223						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1224						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1225						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1226						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1227						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1228						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1229						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1230						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1231						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1232						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1233						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1234						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1235						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1236						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1237						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1238						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1239						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1240						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1241						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1242						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1243						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1244						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1245						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1246						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1247						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1248						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1249						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1250						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1251						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1252						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1253						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1254						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1255						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1256						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1257						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1258						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1259						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1260						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1261						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1262						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1263						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1264						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1265						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1266						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1267						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1268						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1269						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1270						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1271						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1272						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1273						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1274						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1275						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1276						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1277						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1278						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1279						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1280						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1281						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1282						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1283						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1284						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1285						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1286						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1287						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1288						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1289						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1290						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1291						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1292						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1293						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1294						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1295						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1296						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1297						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1298						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1299						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1300						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1301						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1302						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1303						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1304						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1305						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1306						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1307						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1308						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1309						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1310						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1311						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1312						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1313						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1314						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1315						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1316						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1317						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1318						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1319						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1320						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1321						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1322						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1323						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1324						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1325						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1326						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1327						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1328						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1329						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1330						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1331						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1332						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1333						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1334						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1335						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1336						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1337						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1338						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1339						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1340						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1341						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1342						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1343						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1344						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1345						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1346						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1347						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1348						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1349						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1350						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1351						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1352						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1353						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1354						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1355						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1356						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1357						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1358						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1359						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1360						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1361						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1362						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1363						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1364						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1365						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1366						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1367						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1368						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1369						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1370						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1371						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1372						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1373						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1374						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1375						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1376						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1377						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1378						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1379						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1380						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1381						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

No.	Trial Exhibit	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1382							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1383							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1384							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1385							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1386							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1387							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1388							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1389							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1390							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1391							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1392							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1393							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1394							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1395							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1396							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1397							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1398							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1399							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1400							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1401							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1402							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1403							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1404							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1405							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1406							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1407							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1408							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1409							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1410							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1411							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1412							RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1413							RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1414						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1415						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1416						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1417						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1418						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1419						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1420						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1421						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1422						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1423						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1424						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1425						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1426						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1427						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1428						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1429						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1430						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1431						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1432						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1433						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1434						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1435						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1436						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1437						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1438						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1439						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1440						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1441						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1442						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1443						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1444						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1445						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1446						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1447						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1448						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1449						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1450						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1451						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1452						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1453						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1454						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1455						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1456						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1457						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1458						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1459						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1460						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1461						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1462						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1463						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1464						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1465						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1466						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1467						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1468						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1469						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1470						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1471						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1472						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1473						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1474						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1475						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1476						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1477						RESERVED FOR CASE-SPECIFIC EXHIBITS



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1478						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1479						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1480						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1481						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1482						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1483						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1484						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1485						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1486						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1487						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1488						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1489						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1490						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1491						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1492						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1493						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1494						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1495						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1496						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1497						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1498						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1499						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1500						RESERVED FOR CASE-SPECIFIC EXHIBITS
D-1501						EPS/TD Video
D-1502					Relevance; FRE 404; Impermissible character evidence	Demonstrative 1 as provided to plaintiffs
D-1503					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 2 as provided to plaintiffs
						Demonstrative 3 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

___ Government ___ Plaintiff ___ Defendant ___ X ___ Joint ___ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1504					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 4 as provided to plaintiffs
D-1505					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 5 as provided to plaintiffs
D-1506					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 6 as provided to plaintiffs
D-1507					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 7 as provided to plaintiffs
D-1508					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 8 as provided to plaintiffs
D-1509					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 9 as provided to plaintiffs
D-1510					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 10 as provided to plaintiffs
D-1511					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 11 as provided to plaintiffs
D-1512					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 12 as provided to plaintiffs
D-1513					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 13 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1514					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 14 as provided to plaintiffs
D-1515					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 15 as provided to plaintiffs
D-1516					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 16 as provided to plaintiffs
D-1517					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 17 as provided to plaintiffs
D-1518					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 18 as provided to plaintiffs
D-1519					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 19 as provided to plaintiffs
D-1520					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 20 as provided to plaintiffs
D-1521					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 21 as provided to plaintiffs
D-1522					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 22 as provided to plaintiffs
D-1523					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 23 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1524					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 24, revised, as provided to plaintiffs
D-1525					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 25 as provided to plaintiffs
D-1526					Foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 26 as provided to plaintiffs
D-1527					Assumes facts not in evidence; foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 27 as provided to plaintiffs
D-1528					Assumes facts not in evidence; foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 28 as provided to plaintiffs
D-1529					Assumes facts not in evidence; foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 29 as provided to plaintiffs
D-1530					Assumes facts not in evidence; foundation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 30 as provided to plaintiffs
D-1531						Demonstrative 31 as provided to plaintiffs
D-1532						Demonstrative 32 as provided to plaintiffs
D-1533						Demonstrative 33 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1534					FRE 403; prejudice outweighs probative value/confusion; assumes facts not in evidence; foundation; mischaracterizes evidence	Demonstrative 34 as provided to plaintiffs
D-1535					Speculation; assumes facts not in evidence; mischaracterizes evidence; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 35 as provided to plaintiffs
D-1536					Speculation; assumes facts not in evidence; mischaracterizes evidence; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 36 as provided to plaintiffs
D-1537					Speculation; assumes facts not in evidence; mischaracterizes evidence; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 37 as provided to plaintiffs
D-1538					Speculation; assumes facts not in evidence; mischaracterizes evidence; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 38 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff Joint _____ Court _____
 Case No. 6:06-cv-1769-ACC-DAB
Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1539					Speculation; assumes facts not in evidence; mischaracterizes evidence; FRE: 403; prejudice outweighs probative value/confusion	Demonstrative 39 as provided to plaintiffs
D-1540					Speculation; assumes facts not in evidence; mischaracterizes evidence; FRE: 403; prejudice outweighs probative value/confusion	Demonstrative 40 as provided to plaintiffs
D-1541					Mischaracterizes evidence; foundation; speculation; impermissible scientific evidence; FRE: 403; prejudice outweighs probative value/confusion	Demonstrative 41 as provided to plaintiffs
D-1542					Mischaracterizes evidence; foundation; speculation; impermissible scientific evidence; FRE: 403; prejudice outweighs probative value/confusion	Demonstrative 42, revised, as provided to plaintiffs
D-1543					Relevance; mischaracterizes evidence; FRE: 403; prejudice outweighs probative value/confusion; foundation	Demonstrative 43 as provided to plaintiffs
D-1544						Demonstrative 44 as provided to plaintiffs
D-1545						Demonstrative 45 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1546					FRE 403; prejudice outweighs probative value/confusion; mischaracterizes evidence; foundation	Demonstrative 46 as provided to plaintiffs
D-1547					FRE 403; prejudice outweighs probative value/confusion; hearsay; mischaracterizes evidence	Demonstrative 47 as provided to plaintiffs
D-1548						Demonstrative 48 as provided to plaintiffs
D-1549						Demonstrative 49 as provided to plaintiffs
D-1550					Speculation; Hearsay; FRE 403; prejudice outweighs probative value/confusion; foundation	Demonstrative 50 as provided to plaintiffs
D-1551					Speculation; Hearsay; FRE 403; prejudice outweighs probative value/confusion; foundation	Demonstrative 51 as provided to plaintiffs
D-1552					Foundation; assumes facts not in evidence; mischaracterizes evidence; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 52 as provided to plaintiffs
D-1553					Hearsay; speculation; assumes facts not in evidence; mischaracterizes evidence	Demonstrative 53 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1554					FRE 403; prejudice outweighs probative value/confusion; hearsay; speculation	Demonstrative 54 as provided to plaintiffs
D-1555					Hearsay; assumes facts not in evidence; mischaracterizes evidence; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 55 as provided to plaintiffs
D-1556						Demonstrative 56 as provided to plaintiffs
D-1557					Hearsay	Demonstrative 57 as provided to plaintiffs
D-1558					Assumes facts not in evidence; FRE 403; prejudice outweighs probative value/confusion; mischaracterizes evidence; foundation	Demonstrative 58 as provided to plaintiffs
D-1559					Hearsay; FRE 403; prejudice outweighs probative value/confusion; mischaracterizes evidence	Demonstrative 59 as provided to plaintiffs
D-1560					Hearsay; FRE 403; prejudice outweighs probative value/confusion; mischaracterizes evidence	Demonstrative 60 as provided to plaintiffs
D-1561						Demonstrative 61 as provided to plaintiffs
D-1562						Demonstrative 62 as provided to plaintiffs
D-1563						Demonstrative 63 as provided to plaintiffs
D-1564						Demonstrative 64 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1565					Mischaracterizes evidence; FRE 403; prejudice outweighs probative value/confusion; assumes facts not in evidence	Demonstrative 65 as provided to plaintiffs
D-1566					Hearsay; mischaracterizes evidence; assumes facts not in evidence; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 66 as provided to plaintiffs
D-1567					Speculation; impermissible scientific evidence	Demonstrative 67 as provided to plaintiffs
D-1568					Speculation	Demonstrative 68 as provided to plaintiffs
D-1569					Speculation	Demonstrative 69 as provided to plaintiffs
D-1570					Speculation	Demonstrative 70 as provided to plaintiffs
D-1571					Hearsay; mischaracterizes evidence	Demonstrative 71 as provided to plaintiffs
D-1572					Hearsay; mischaracterizes evidence	Demonstrative 72 as provided to plaintiffs
D-1573					FRE 403; prejudice outweighs probative value/confusion	Demonstrative 73 as provided to plaintiffs
D-1574					Hearsay; speculation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 74 as provided to plaintiffs
D-1575					Hearsay; speculation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 75 as provided to plaintiffs
D-1576					Hearsay; speculation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 76 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1577					Hearsay; mischaracterizes evidence	Demonstrative 77 as provided to plaintiffs
D-1578					Hearsay; mischaracterizes evidence	Demonstrative 78 as provided to plaintiffs
D-1579					Hearsay; mischaracterizes evidence	Demonstrative 79 as provided to plaintiffs
D-1580						Demonstrative 80 as provided to plaintiffs
D-1581						Demonstrative 81 as provided to plaintiffs
D-1582						Demonstrative 82 as provided to plaintiffs
D-1583					FRE 403; prejudice outweighs probative value/confusion; hearsay; assumes facts not in evidence	Demonstrative 83 as provided to plaintiffs
D-1584						Demonstrative 84 as provided to plaintiffs
D-1585					Hearsay; FRE 403; prejudice outweighs probative value/confusion; mischaracterizes evidence	Demonstrative 85 as provided to plaintiffs
D-1586					Hearsay; FRE 403; prejudice outweighs probative value/confusion; mischaracterizes evidence	Demonstrative 86 as provided to plaintiffs
D-1587					Argumentative; speculation; mischaracterizes evidence	Demonstrative 87 as provided to plaintiffs
D-1588					Speculation; mischaracterizes evidence	Demonstrative 88 as provided to plaintiffs
D-1589					Mischaracterizes evidence; speculation	Demonstrative 89 as provided to plaintiffs
D-1590						Demonstrative 90 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1591					Hearsay; FRE 403; prejudice outweighs probative value/confusion; mischaracterizes evidence	Demonstrative 91 as provided to plaintiffs
D-1592						Demonstrative 92 as provided to plaintiffs
D-1593						Demonstrative 93 as provided to plaintiffs
D-1594						Demonstrative 94 as provided to plaintiffs
D-1595						Demonstrative 95 as provided to plaintiffs
D-1596						Demonstrative 96 as provided to plaintiffs
D-1597						Demonstrative 97, revised, as provided to plaintiffs
D-1598						Demonstrative 98 as provided to plaintiffs
D-1599						Demonstrative 99 as provided to plaintiffs
D-1600						Demonstrative 100 as provided to plaintiffs
D-1601						Demonstrative 101 as provided to plaintiffs
D-1602						Demonstrative 102 as provided to plaintiffs
D-1603						Demonstrative 103 as provided to plaintiffs
D-1604						Demonstrative 104 as provided to plaintiffs
D-1605						Demonstrative 105 as provided to plaintiffs
D-1606						Demonstrative 106 as provided to plaintiffs
D-1607						Demonstrative 107 as provided to plaintiffs
D-1608						Demonstrative 108 as provided to plaintiffs
D-1609						Demonstrative 109 as provided to plaintiffs
D-1610						Demonstrative 110 as provided to plaintiffs
D-1611						Demonstrative 111 as provided to plaintiffs
D-1612						Demonstrative 112 as provided to plaintiffs
D-1613						Demonstrative 113 as provided to plaintiffs
D-1614						Demonstrative 114 as provided to plaintiffs
D-1615						Demonstrative 115 as provided to plaintiffs
D-1616						Demonstrative 116 as provided to plaintiffs
D-1617						Demonstrative 117 as provided to plaintiffs
D-1618						Demonstrative 118 as provided to plaintiffs
D-1619						Demonstrative 119 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1620						Demonstrative 120 as provided to plaintiffs
D-1621					Speculation; mischaracterizes evidence; assumes facts not in evidence; FRE 403; prejudice outweighs probative value/ confusion; hearsay	Demonstrative 121 as provided to plaintiffs
D-1622					Speculation; mischaracterizes evidence; assumes facts not in evidence; FRE 403; prejudice outweighs probative value/ confusion; hearsay	Demonstrative 122 as provided to plaintiffs
D-1623					Speculation; mischaracterizes evidence; assumes facts not in evidence; FRE 403; prejudice outweighs probative value/ confusion; hearsay	Demonstrative 123 as provided to plaintiffs
D-1624					Speculation; mischaracterizes evidence; assumes facts not in evidence; FRE 403; prejudice outweighs probative value/ confusion; hearsay	Demonstrative 124 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1625					Speculation; mischaracterizes evidence; assumes facts not in evidence; FRE 403; prejudice outweighs probative value/ confusion; hearsay	Demonstrative 125 as provided to plaintiffs
D-1626					Speculation; mischaracterizes evidence; assumes facts not in evidence; FRE 403; prejudice outweighs probative value/ confusion; hearsay	Demonstrative 126 as provided to plaintiffs
D-1627					Speculation; mischaracterizes evidence; assumes facts not in evidence; FRE 403; prejudice outweighs probative value/ confusion; hearsay	Demonstrative 127 as provided to plaintiffs
D-1628						Demonstrative 128 as provided to plaintiffs
D-1629						Demonstrative 129 as provided to plaintiffs
D-1630						Demonstrative 130 as provided to plaintiffs
D-1631						Demonstrative 131 as provided to plaintiffs
D-1632						Demonstrative 132 as provided to plaintiffs
D-1633						Demonstrative 133 as provided to plaintiffs
D-1634					Speculation; FRE 403; prejudice outweighs probative value/ confusion	Demonstrative 134 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1635					FRE 403; prejudice outweighs probative value/confusion; hearsay; mischaracterizes evidence	Demonstrative 135 as provided to plaintiffs
D-1636					FRE 403; prejudice outweighs probative value/confusion; hearsay; mischaracterizes evidence	Demonstrative 136 as provided to plaintiffs
D-1637					Speculation	Demonstrative 137 as provided to plaintiffs
D-1638					FRE 403; prejudice outweighs probative value/confusion; speculation	Demonstrative 138 as provided to plaintiffs
D-1639					Hearsay; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 139 as provided to plaintiffs
D-1640					Speculation	Demonstrative 140 as provided to plaintiffs
D-1641					Speculation	Demonstrative 141 as provided to plaintiffs
D-1642					Speculation	Demonstrative 142 as provided to plaintiffs
D-1643					Speculation; mischaracterizes evidence; assumes facts not in evidence; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 143 as provided to plaintiffs
D-1644						Demonstrative 144 as provided to plaintiffs
D-1645						Demonstrative 145 as provided to plaintiffs
D-1646					Speculation; FRE 403; prejudice outweighs probative value/confusion	Demonstrative 146 as provided to plaintiffs
D-1647					Speculation; mischaracterizes evidence; assumes facts not in evidence	Demonstrative 147 as provided to plaintiffs
D-1648						Demonstrative 148 as provided to plaintiffs
D-1649						Demonstrative 149 as provided to plaintiffs
D-1650						Demonstrative 150 as provided to plaintiffs



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1651						Demonstrative 151 as provided to plaintiffs
D-1652					FIRE 403; prejudice outweighs probative value/confusion; foundation	Demonstrative 152 as provided to plaintiffs
D-1653					Speculation; FIRE 403; prejudice outweighs probative value/confusion	Demonstrative 153 as provided to plaintiffs
D-1654					Mischaracterizes evidence	Demonstrative 154 as provided to plaintiffs
D-1655	Leong 3					Summary of 7/2003 SERM Discussion Document. (Leong Ex. 3)
D-1656	Leong DX 4					Summary of SERMs. (Leong Ex. 4)
D-1657	Brecher 59					AZ Clinical Trials Website. (Brecher Ex. 59)
D-1658						Demonstrative 155 as provided to plaintiff.
D-1659	Scott 34					Demonstrative - Mark Scott Notes re Clinical Trials
D-1660	Scott 36					Seroquel Timeline
D-1661						RESERVED FOR DEMONSTRATIVES
D-1662						RESERVED FOR DEMONSTRATIVES
D-1663						RESERVED FOR DEMONSTRATIVES
D-1664						RESERVED FOR DEMONSTRATIVES
D-1665						RESERVED FOR DEMONSTRATIVES
D-1666						RESERVED FOR DEMONSTRATIVES
D-1667						RESERVED FOR DEMONSTRATIVES
D-1668						RESERVED FOR DEMONSTRATIVES
D-1669						RESERVED FOR DEMONSTRATIVES
D-1670						RESERVED FOR DEMONSTRATIVES
D-1671						RESERVED FOR DEMONSTRATIVES
D-1672						RESERVED FOR DEMONSTRATIVES
D-1673						RESERVED FOR DEMONSTRATIVES
D-1674						RESERVED FOR DEMONSTRATIVES
D-1675						RESERVED FOR DEMONSTRATIVES



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
D-1676						RESERVED FOR DEMONSTRATIVES
D-1677						RESERVED FOR DEMONSTRATIVES
D-1678						RESERVED FOR DEMONSTRATIVES
D-1679						RESERVED FOR DEMONSTRATIVES
D-1680						RESERVED FOR DEMONSTRATIVES
D-1681						RESERVED FOR DEMONSTRATIVES
D-1682						RESERVED FOR DEMONSTRATIVES
D-1683						RESERVED FOR DEMONSTRATIVES
D-1684						RESERVED FOR DEMONSTRATIVES
D-1685						RESERVED FOR DEMONSTRATIVES
D-1686						RESERVED FOR DEMONSTRATIVES
D-1687						RESERVED FOR DEMONSTRATIVES
D-1688						RESERVED FOR DEMONSTRATIVES
D-1689						RESERVED FOR DEMONSTRATIVES
D-1690						RESERVED FOR DEMONSTRATIVES
D-1691						RESERVED FOR DEMONSTRATIVES
D-1692						RESERVED FOR DEMONSTRATIVES
D-1693						RESERVED FOR DEMONSTRATIVES
D-1694						RESERVED FOR DEMONSTRATIVES
D-1695						RESERVED FOR DEMONSTRATIVES
D-1696						RESERVED FOR DEMONSTRATIVES
D-1697						RESERVED FOR DEMONSTRATIVES
D-1698						RESERVED FOR DEMONSTRATIVES
D-1699						RESERVED FOR DEMONSTRATIVES
J-1	Limp 8, McKenna DX 63					10/15/2003. Letter from AZ to FDA Acknowledging FDA's 9/11/03 Request for Class Warning. (AZ/SER05316807 - AZ/SER05316808)



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff Defendant Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Supplated Admissions	Description of Exhibit
J-2	Arnold DX 100, Fors 30, Goldstein DX 100, McKenna DX 2, Patterson DX 100					9/26/1997. Letter from FDA to AZ Approving Seroquel for Management of Manifestations of Psychotic Disorders. (AZ/SER10188109 - AZ/SER10188135)
J-3	Arnold 12					2/19/2004. SERM Minutes. (AZSER10415511)
J-4	Arnold 9, Limp 21, McKenna 11, Rak 19, Warner 11					6/8/2007. SERM Minutes. (AZSER23260840 - AZSER23260841)
J-5	Brecher 31 Zook 9 (under AZ/SER 6951509-17)					4/5/2001. SERM Justification Document re Weight Gain. (AZSER06773568 - AZSER06773577)
J-6	Leong 2					American Diabetes Association, et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. <i>Diabetes Care</i> . 2004; 27(2): 596-601.
J-7						Barner, J et al. Frequency of New-Onset Diabetes Mellitus and Use of Antipsychotic Drugs Among Central Texas Veterans. <i>Pharmacotherapy</i> . 2004; 24(11): 1529-1538.
J-8						Bobes, J et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the FIRE study. <i>Schizophrenia Research</i> . 2003; 62: 77-88.



JOINT TRIAL EXHIBIT LIST

Government Plaintiff Defendant X Joint Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
J-9						Buse, J et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. <i>Journal of Clinical Epidemiology</i> . 2003; 56: 164-170.
J-10	Calabrese 13					Calabrese JR et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression. <i>American Journal of Psychiatry</i> . 2005; 162:1351-1360.
J-11						Cassidy, F. Elevated Frequency of Diabetes Mellitus in Hospitalized Manic-Depressive Patients. <i>American Journal of Psychiatry</i> . 1999; 156:1417-1420.
J-12						Copolov, D et al. A Multicentre, Double-Blind, Randomized Comparison (ICI 204,636 Serroquel) and Haloperidol in Schizophrenia. <i>Psychological Medicine</i> . 2000; 30: 95-105.
J-13	Schwartz 57					Gianfrancesco, F et al. Antipsychotic-Induced Type 2 Diabetes: Evidence from a Large Health Plan Database. <i>Journal of Clinical Psychopharmacology</i> . 2003; 23: 328-335.
J-14						Gupta, S et al. Hyperglycemia and Hypertiglyceridemia in Real World Patients on Antipsychotic Therapy. <i>American Journal of Therapeutics</i> . 2003; 10: 348-355.
J-15						Lambert, B et al. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. <i>Pharmacoeconomics and Drug Safety</i> . 2005; 14(6): 417-425.
J-16						Leslie, D et al. Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications. <i>American Journal of Psychiatry</i> . 2004; 161: 1709-1711.
J-17						Melnyov, J et al. Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> . 2006; 163: 600-610.



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
J-18						McEvoy, J et al. Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52 Week Comparison. <i>American Journal of Psychiatry</i> . 2007; 164: 1050-1060.
J-19						Sernyak, M. Undiagnosed Hyperglycemia in Patients Treated with Atypical Antipsychotics. <i>Journal of Clinical Psychiatry</i> . 2005; 66: 1463-1467.
J-20						Stroup, T et al. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> . 2006; 163: 611-622.
J-21						Stroup, T et al. Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study. <i>American Journal of Psychiatry</i> . 2007; 164: 415-427.
J-22	Gaskill 53					7/15/2002. SERM Justification Document re Weight Gain. (AZSER10480425 - AZSER10480433)
J-23	MacFadden 5, Jackson 55, Linn 304					4/22/2004. Revised "Dear HCP Letter." (AZSER10376375 - AZSER10376377)
J-24	Linn 9, Linn 69					12/5/2003. Notes of Teleconference between AZ and FDA re: Proposed Class Warning re DM. (AZSER08789738 - AZSER08789739)
J-25	Arnold DX 215					2/19/2004. SERM Discussion Document re Glucose Dysregulation. (AZSER10478763 - AZSER10478876)
J-26						1/23/2004. Zook e-mail re OPMT Feedback. (AZ/SER3791849 - AZ/SER3791850)
J-27						12/17/2002. SERM Minutes. (AZSER10415506 - AZSER10415507)



JOINT TRIAL EXHIBIT LIST

Government _____ Plaintiff _____ Defendant X Joint _____ Court
 Case No. 6:06-cv-1769-ACC-DAB
 Style: IN RE: SEROQUEL PRODUCTS LIABILITY LITIGATION

Trial Exhibit No.	Depo. Ex.	Date Identified	Date Admitted	Sponsoring Witness	Objections/Stipulated Admissions	Description of Exhibit
J-28						12/17/1999, FDA Review of Atypical Anti-Psychotics re New-onset Diabetes Mellitus. (FDACDER 003795 - FDACDER 003808)